Diabetes, metformin use and risk of non‐ Hodgkin's lymphoma in postmenopausal women: A prospective cohort analysis in the Women's Health Initiative
International Journal of Cancer · 15.04.2023 · 152 (8) · 1556-1569
DOI: 10.1002/ijc.34376 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 07.12.2022. Verfasst von Zikun Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, School of Public Health, Indiana University Bloomington, Bloomington, Indiana, USA. Hauptthemen laut MEDLINE: Metformin, Lymphoma, Non-Hodgkin, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Epidemiologic evidence is limited about associations between T2DM, metformin, and the risk of non‐Hodgkin's lymphoma (NHL). We aimed to examine associations between T2DM, metformin, and the risk of NHL in the Women's Health Initiative (WHI) Study. Information on T2DM status (diabetes status/types of antidiabetic drug use/diabetes duration) from study enrollment and during follow‐up were assessed. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to evaluate associations of T2DM status with risks of overall NHL and its three major subtypes [diffuse large B‐cell lymphoma (DLBCL, n = 476), follicular lymphoma (FL, n = 301) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL, n = 136)] based on multivariable‐adjusted Cox proportional hazards models. During a median follow‐up of 18.86 years (range, 0.01‐25.13; SD ± 6.55), a total of 1637 women developed NHL among 147 885 postmenopausal women. Women with T2DM and with self‐reported oral medication use had 38% and 55% higher risk of DLBCL, respectively [multivariable‐adjusted model HR = 1.38, 95% CI (1.06‐1.81) and HR = 1.55, 95% CI (1.16‐2.06)] compared to the reference group (nondiabetics/untreated diabetes). Risks of NHL and DLBCL [multivariable‐adjusted model: HR = 1.28, 95% CI (1.06‐1.54) and HR = 1.56, 95% CI (1.13‐2.14), respectively] were significantly higher in associations with relatively short duration (≤7 years) of diabetes, compared to reference group. Additionally, an increased risk of DLBCL [HR = 1.76, 95% CI (1.13‐2.75)] was found in metformin users compared to the reference group. Postmenopausal women who had T2DM, who were oral antidiabetic drug users, especially metformin, and who had a shorter diabetes duration may have higher risks of DLBCL. Further well‐designed research is needed to confirm our findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, School of Public Health, Indiana University Bloomington, Bloomington, Indiana, USA.
- Atlanta VA Medical Center, Decatur, Georgia, USA.
- Division of Endocrinology, Emory University School of Medicine, Atlanta, Georgia, USA.
- Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.
- Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, California, USA.
- Department of Pharmacology and Toxicology, Medical Sciences Program, Indiana University School of Medicine-Bloomington, Bloomington, Indiana, USA.
ORCID-Profile: Zikun Wang, Juhua Luo
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Wang, Z., Phillips, L. S., Rohan, T. E., Ho, G. Y. F., Shadyab, A. H., Bidulescu, A., Rudick, C. N., Pan, K., Chen, Z., & Luo, J. (2023). Diabetes, metformin use and risk of non‐ Hodgkin's lymphoma in postmenopausal women: A prospective cohort analysis in the Women's Health Initiative. International Journal of Cancer, 152(8), 1556-1569. https://doi.org/10.1002/ijc.34376
Vancouver
Wang Z, Phillips LS, Rohan TE, Ho GYF, Shadyab AH, Bidulescu A, et al. Diabetes, metformin use and risk of non‐ Hodgkin's lymphoma in postmenopausal women: A prospective cohort analysis in the Women's Health Initiative. International Journal of Cancer. 2023;152(8):1556-1569. doi:10.1002/ijc.34376
BibTeX
@article{Wang2023,
author = {Wang, Zikun and Phillips, Lawrence S and Rohan, Thomas E and Ho, Gloria Y F and Shadyab, Aladdin H and Bidulescu, Aurelian and Rudick, Charles N and Pan, Kathy and Chen, Zhongxue and Luo, Juhua},
title = {Diabetes, metformin use and risk of non‐ Hodgkin's lymphoma in postmenopausal women: A prospective cohort analysis in the Women's Health Initiative},
journal = {International Journal of Cancer},
year = {2023},
volume = {152},
number = {8},
pages = {1556--1569},
doi = {10.1002/ijc.34376}
}
EUVIMED